Adani Enterp.
2507.9 -35.80
Adani Ports
1405 -40.80
Apollo Hospitals
6994.5 -2.00
Asian Paints
2214.2 -5.20
Axis Bank
1205.8 -7.10
Bajaj Auto
8463.5 -103.50
Bajaj Finance
9331 -37.50
Bajaj Finserv
2011 -17.80
Bharat Electron
394.2 6.80
Bharti Airtel
1840.4 -3.80
Cipla
1505.2 2.40
Coal India
391.2 -1.50
Dr Reddy's Labs
1362.5 -0.20
Eicher Motors
5319 3.50
Eternal Ltd
249.08 -2.48
Grasim Inds
2663.8 -25.30
HCL Technologies
1695.3 -5.90
HDFC Bank
1917.6 -25.80
HDFC Life Insur.
752.85 -1.65
Hero Motocorp
4333.8 -29.00
Hind. Unilever
2319 -13.70
Hindalco Inds.
641.8 -9.25
ICICI Bank
1416.1 -9.10
IndusInd Bank
816.85 -13.05
Infosys
1602 -6.60
ITC
413.9 -7.10
JSW Steel
987.25 -8.40
Kotak Mah. Bank
2107.4 -19.40
Larsen & Toubro
3587.4 -16.50
M & M
3006 -13.20
Maruti Suzuki
12408 18.00
Nestle India
2376.8 -8.80
NTPC
331.95 -1.75
O N G C
251.51 3.63
Power Grid Corpn
285.5 -3.50
Reliance Industr
1427.9 -13.70
SBI Life Insuran
1755.2 -10.80
Shriram Finance
667.15 -0.90
St Bk of India
792.35 -13.60
Sun Pharma.Inds.
1687.8 0.40
Tata Consumer
1078.4 -6.70
Tata Motors
712.05 -3.30
Tata Steel
152.13 -0.76
TCS
3445.7 11.50
Tech Mahindra
1659 14.60
Titan Company
3421.9 -30.80
Trent
5590 -37.50
UltraTech Cem.
11224 -99.00
Wipro
260.21 0.60
The primary objective of the scheme is to provide long-term capital appreciation by investing primarily in equity and equity-related instruments of companies operating in the pharmaceutical and healthcare sectors. At least 80% of the fund's assets will be allocated to businesses in these areas, including allied service providers.
The fund adopts an actively managed approach with a bottom-up stock selection strategy. It does not have a specific market capitalization preference, allowing for investments across large-cap, mid-cap, and small-cap companies. The fund will be managed by Sanjay Chawla. It carries an exit load of 1% if redeemed within 365 days. The minimum investment during the NFO is set at Rs 1,000.
India's healthcare market, valued at approximately US$ 110 billion in FY16, is projected to grow to US$ 638 billion by FY25, with an estimated annual growth rate of 22%. This growth is supported by rising demand, technological advancements, and expanding infrastructure.
The fund aims to provide diversified exposure across the entire healthcare value chain. This includes pharmaceuticals and biotechnology, API manufacturers, and contract research and manufacturing organizations (CROs/CDMOs). It also covers hospitals, diagnostics, and medical devices, along with pharmacy retail. Additionally, the fund taps into the growing wellness segment, investing in fitness centers, nutritional supplements, and assisted living services.
Positioned as a long-term investment option, the scheme is aimed at investors seeking to benefit from the structural growth and increasing relevance of healthcare in India's economic development. It is suitable for those with an investment horizon of three years or more, looking to participate in a sector that plays a critical role in improving societal well-being and supporting sustainable development.
Powered by Capital Market - Live News